E. K.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

E. K., Uta Bertsch, Jan Dürig et al. · Leukemia · 2015 · 140 citations

Hematological Malignancy, Oncology, Versus Bortezomib +7

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

Maximilian Merz, Hans Salwender, Mathias Haenel et al. · Haematologica · 2015 · 71 citations · Full text

Hematological Malignancy, Oncology, Overall Response Rates +14

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma

E. K., Thomas Hielscher, J.K. Kloth et al. · Haematologica · 2015 · 51 citations · Full text

The Xpert® MTB/RIF assay evaluation in South Korea, a country with an intermediate tuberculosis burden

Su Yeong Kim, Hyun‐Chang Kim, Su Yeong Kim et al. · The International Journal of Tuberculosis and Lung Disease · 2012 · 17 citations